Exhibit 99.1

 

LOGO

Vanda Pharmaceuticals Reports First Quarter 2018 Financial Results

 

    Total net product sales were $43.6 million in the first quarter of 2018

 

    Vanda reiterates 2018 net product sales guidance of $180 million to $200 million

WASHINGTON – May 2, 2018 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2018.

“We are pleased with the progress made in 2018 with the continued growth of our HETLIOZ business and the successful defense of our U.S. Fanapt franchise,” said Mihael H. Polymeropoulos, M.D., Vanda’s President and CEO. “Our research and development programs are progressing including life cycle management of commercialized products and the advancement of our late stage clinical pipeline.”

Key Highlights:

 

    Total net product sales from HETLIOZ® and Fanapt® were $43.6 million during the first quarter of 2018, a 2% decrease compared to $44.3 million in the fourth quarter of 2017 and a 17% increase compared to $37.4 million in the first quarter of 2017.

 

    In March 2018, Vanda completed a public offering of its common stock that resulted in net proceeds of $100.9 million.

HETLIOZ® (tasimelteon)

 

    HETLIOZ® net product sales were $25.4 million in the first quarter of 2018, a 2% increase compared to $25.0 million in the fourth quarter of 2017 and a 26% increase compared to $20.2 million in the first quarter of 2017.

 

    In April 2018, Vanda filed a lawsuit against Teva Pharmaceuticals USA, Inc. for infringement of HETLIOZ® patents by submitting to the U.S. Food and Drug Administration (the FDA) an Abbreviated New Drug Application for a generic version of HETLIOZ® prior to the expiration of the latest to expire of Vanda’s HELTIOZ® patents in 2034.

Fanapt® (iloperidone)

 

    Fanapt® net product sales were $18.2 million in the first quarter of 2018, a 6% decrease compared to $19.3 million in the fourth quarter of 2017 and a 5% increase compared to $17.2 million in the first quarter of 2017.

 

    Fanapt® prescriptions, as reported by IQVIA, were 27,372 in the first quarter of 2018, a 3% decrease compared to the fourth quarter of 2017.

 

    In April 2018, the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delaware’s decision that West Ward Pharmaceuticals, a subsidiary of Hikma Pharmaceuticals, infringed Vanda’s U.S. Patent number 8,586,610 (the ‘610 Patent) for Fanapt®. The ‘610 Patent is set to expire November 2, 2027.

Research and Development

Tradipitant

 

    Vanda held an end of Phase II meeting with the FDA in April 2018 to discuss the clinical and regulatory path forward for tradipitant as a treatment for chronic pruritus in atopic dermatitis. A Phase III clinical study is expected to begin in the second quarter of 2018.

 

    A tradipitant clinical study for the treatment of gastroparesis is ongoing. Results are expected by the end of 2018.

 

Page 1 of 7


HETLIOZ®

 

    Results from the JET8 Phase III clinical study to treat jet lag disorder in an 8 hour phase advance (3107) showed significant and clinically meaningful effects of HETLIOZ® 20mg on the primary endpoint of the study as well as multiple secondary endpoints in the treatment of jet lag disorder. Vanda intends to seek U.S. marketing approval for the use of HETLIOZ® in the treatment of jet lag disorder.

 

    A pharmacokinetic study of the HETLIOZ® pediatric liquid formulation is now complete.

 

    Enrollment in the Smith-Magenis Syndrome clinical study is ongoing. Results are expected by the end of 2018.

VTR-297 (histone deacetylase (HDAC) inhibitor)

 

    A VTR-297 Phase I study (1101) in patients with hematologic malignancies is expected to start in the second half of 2018.

Cash, cash equivalents and marketable securities (Cash) were $248.8 million as of March 31, 2018, representing an increase to Cash of $105.4 million during the first quarter of 2018.

Non-GAAP Financial Results

Non-GAAP net income was $6.6 million for the first quarter of 2018, or $0.14 per share, compared to a Non-GAAP net loss of $4.9 million, or $0.11 per share, for the first quarter of 2017.

Vanda provides Non-GAAP financial information, which it believes can enhance an overall understanding of its financial performance when considered together with GAAP figures. Refer to the sections of this press release entitled “Non-GAAP Financial Information” and “Reconciliation of GAAP to Non-GAAP Financial Information” for more detailed information regarding Non-GAAP financial information.

2018 Financial Guidance

Vanda reiterates its prior 2018 financial guidance, updates its year-end 2018 Cash(1) guidance, and expects to achieve the following financial objectives in 2018:

 

Full Year 2018

Financial Objectives

  

Full Year 2018

Guidance

Combined net product sales from both HETLIOZ® and Fanapt®

   $180 to $200 million

HETLIOZ® net product sales

   $108 to $118 million

Fanapt® net product sales

   $72 to $82 million

Non-GAAP Operating expenses, excluding Cost of goods sold(2)

   $163 to $173 million

Intangible asset amortization

   $1.7 million

Stock-based compensation

   $11 to $15 million

Year-end 2018 Cash(1)

  

$215 to $225 million

as compared to prior guidance of

$115 to $125 million

 

(1) Year-end 2018 Cash includes the expected payment of a $25 million milestone obligation based on cumulative HETLIOZ® net product sales and the net proceeds of $100.9 million from the March 2018 public offering.
(2) Non-GAAP Operating expenses, excludes Cost of goods sold, intangible asset amortization and stock-based compensation.

 

Page 2 of 7


Conference Call

Vanda has scheduled a conference call for today, Wednesday, May 2, 2018, at 4:30 PM ET. During the call, Vanda’s management will discuss the first quarter 2018 financial results and other corporate activities. Investors can call 1-888-771-4371 (domestic) or 1-847-585-4405 (international) and use passcode 46823596. A replay of the call will be available on Wednesday, May 2, 2018, beginning at 7:00 PM ET and will be accessible until Wednesday, May 9, 2018, at 11:59 PM ET. The replay call-in number is 1-888-843-7419 for domestic callers and 1-630-652-3042 for international callers. The passcode number is 46823596.

The conference call will be broadcast simultaneously on Vanda’s website, www.vandapharma.com. Investors should click on the Investor Relations tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations. The call will also be archived on Vanda’s website for a period of 30 days.

Non-GAAP Financial Information

Vanda believes that the Non-GAAP financial information provided in this press release can assist investors in understanding and assessing the ongoing economics of Vanda’s business and reflect how it manages the business internally and sets operational goals. Vanda’s “Non-GAAP Selling, general and administrative expenses” and “Non-GAAP Research and development expenses” exclude stock-based compensation. Vanda’s “Non-GAAP Net income (loss),” “Non-GAAP Net income (loss) per share” and “Non-GAAP Operating expenses excluding Cost of goods sold” exclude stock-based compensation and intangible asset amortization.

Vanda believes that excluding the impact of these items better reflects the recurring economic characteristics of its business, as well as Vanda’s use of financial resources and its long-term performance.

This press release includes a projection of 2018 Non-GAAP Operating expenses, excluding Cost of goods sold, a forward-looking Non-GAAP financial measure under the heading “2018 Financial Guidance.” This Non-GAAP financial measure is determined by excluding cost of goods sold, stock-based compensation and intangible asset amortization. Vanda is unable to reconcile this Non-GAAP guidance to GAAP because it is difficult to predict the future impact of these adjustments.

These Non-GAAP financial measures, as presented, may not be comparable to similarly titled measures reported by other companies since not all companies may calculate these measures in an identical manner and, therefore, they are not necessarily an accurate measure of comparison between companies.

The presentation of these Non-GAAP financial measures is not intended to be considered in isolation or as a substitute for guidance prepared in accordance with GAAP. The principal limitation of these Non-GAAP financial measures is that they exclude significant elements that are required by GAAP to be recorded in Vanda’s financial statements. In addition, they are

 

Page 3 of 7


subject to inherent limitations as they reflect the exercise of judgments by management in determining these Non-GAAP financial measures. In order to compensate for these limitations, Vanda presents its Non-GAAP financial guidance in connection with its GAAP guidance. Investors are encouraged to review the reconciliation of our Non-GAAP financial measures to their most directly comparable GAAP financial measure.

About Vanda Pharmaceuticals Inc.

Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS

Various statements in this release, including, but not limited to, the guidance provided under “2018 Financial Guidance” above, are “forward-looking statements” under the securities laws. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda’s forward-looking statements include, among others, Vanda’s assumptions regarding its ability to continue to grow its business in the U.S. through the HETLIOZ® to Psychiatrists Initiative, among other means, Vanda’s ability to complete the clinical development and obtain regulatory approval of tradipitant for the treatment of chronic pruritus in atopic dermatitis, Vanda’s ability to successfully commercialize HETLIOZ® in Europe and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Vanda’s annual report on Form 10-K for the fiscal year ended December 31, 2017, which is on file with the SEC and available on the SEC’s website at www.sec.gov. Additional factors may be described in those sections of Vanda’s quarterly report on Form 10-Q for the quarter ended March 31, 2018, to be filed with the SEC in the second quarter of 2018. In addition to the risks described above and in Vanda’s annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda’s results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Page 4 of 7


VANDA PHARMACEUTICALS INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except for share and per share amounts)

(unaudited)

 

     Three Months Ended  
     March 31     March 31  
     2018     2017  

Revenues:

    

HETLIOZ® product sales, net

   $ 25,423     $ 20,182  

Fanapt® product sales, net

     18,169       17,233  
  

 

 

   

 

 

 

Total revenues

     43,592       37,415  

Operating expenses:

    

Cost of goods sold excluding amortization

     4,560       4,003  

Research and development

     9,416       10,567  

Selling, general and administrative

     26,822       30,297  

Intangible asset amortization

     352       454  
  

 

 

   

 

 

 

Total operating expenses

     41,150       45,321  
  

 

 

   

 

 

 

Income (loss) from operations

     2,442       (7,906

Other income

     622       280  
  

 

 

   

 

 

 

Income (loss) before income taxes

     3,064       (7,626

Provision (benefit) for income taxes

     (2     19  
  

 

 

   

 

 

 

Net income (loss)

   $ 3,066     $ (7,645
  

 

 

   

 

 

 

Net income (loss) per share, basic

   $ 0.07     $ (0.17

Net income (loss) per share, diluted

   $ 0.06     $ (0.17

Weighted average shares outstanding, basic

     46,336,430       44,398,359  

Weighted average shares outstanding, diluted

     48,225,041       44,398,359  

 

Page 5 of 7


VANDA PHARMACEUTICALS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

 

     March 31     December 31  
     2018 (1)     2017 (1)  

ASSETS

    

Current assets:

    

Cash and cash equivalents

   $ 155,293     $ 33,627  

Marketable securities

     93,541       109,786  

Accounts receivable, net

     23,314       17,601  

Inventory

     1,011       840  

Prepaid expenses and other current assets

     9,276       8,003  
  

 

 

   

 

 

 

Total current assets

     282,435       169,857  

Property and equipment, net

     5,105       5,306  

Intangible assets, net

     25,717       26,069  

Non-current inventory and other

     4,058       4,193  
  

 

 

   

 

 

 

Total assets

   $ 317,315     $ 205,425  
  

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

    

Current liabilities:

    

Accounts payable and accrued liabilities

   $ 17,242     $ 20,335  

Product revenue allowances

     27,713       23,028  

Milestone obligations under license agreements

     27,000       27,000  
  

 

 

   

 

 

 

Total current liabilities

     71,955       70,363  

Other non-current liabilities

     4,216       3,675  
  

 

 

   

 

 

 

Total liabilities

     76,171       74,038  

Stockholders’ equity:

    

Common stock

     52       45  

Additional paid-in capital

     599,480       492,802  

Accumulated other comprehensive loss

     (28     (34

Accumulated deficit

     (358,360     (361,426
  

 

 

   

 

 

 

Total stockholders’ equity

     241,144       131,387  
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 317,315     $ 205,425  
  

 

 

   

 

 

 

 

(1) With the adoption of Accounting Standards Codification Subtopic 606 Revenue from Contracts with Customers on January 1, 2018, provision for product returns is included in product revenue allowances and other non-current liabilities in the current year. Provision for product returns is included in accounts receivable, net in the prior year. Refer to footnote 2 in the quarterly report on Form 10Q for the quarter ending March 31, 2018.

 

Page 6 of 7


VANDA PHARMACEUTICALS INC.

Reconciliation of GAAP to Non-GAAP Financial Information

(in thousands, except for share and per share amounts)

(unaudited)

 

     Three Months Ended  
     March 31     March 31  
     2018     2017  

Net income (loss)

   $ 3,066     $ (7,645

Adjustments:

    

Stock-based compensation

     3,151       2,256  

Intangible asset amortization

     352       454  
  

 

 

   

 

 

 

Non-GAAP Net income (loss)

   $ 6,569     $ (4,935
  

 

 

   

 

 

 

Non-GAAP Net income (loss) per share, basic

   $ 0.14     $ (0.11

Non-GAAP Net income (loss) per share, diluted

   $ 0.14     $ (0.11

Weighted average shares outstanding, basic

     46,336,430       44,398,359  

Weighted average shares outstanding, diluted

     48,225,041       44,398,359  

Operating expenses

   $ 41,150     $ 45,321  

Adjustments:

    

Cost of goods sold excluding amortization

     (4,560     (4,003

Stock-based compensation

     (3,151     (2,256

Intangible asset amortization

     (352     (454
  

 

 

   

 

 

 

Non-GAAP Operating expenses excluding Cost of goods sold

   $ 33,087     $ 38,608  
  

 

 

   

 

 

 

Research and development

   $ 9,416     $ 10,567  

Adjustment:

    

Stock-based compensation

     (321     (409
  

 

 

   

 

 

 

Non-GAAP Research and development

   $ 9,095     $ 10,158  
  

 

 

   

 

 

 

Selling, general and administrative

   $ 26,822     $ 30,297  

Adjustment:

    

Stock-based compensation

     (2,830     (1,847
  

 

 

   

 

 

 

Non-GAAP Selling, general and administrative

   $ 23,992     $ 28,450  
  

 

 

   

 

 

 

COMPANY CONTACT:

Jim Kelly

Executive Vice President & Chief Financial Officer

Vanda Pharmaceuticals Inc.

(202) 734-3428

jim.kelly@vandapharma.com

SOURCE Vanda Pharmaceuticals Inc.

 

Page 7 of 7

View differences made from one to another to evaluate Vanda Pharmaceuticals Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Vanda Pharmaceuticals Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account